Last edition
News about "Biocon Biologics to Showcase Keytruda"
Biocon Biologics to Showcase Keytruda and Two New Oncology Biosimilars at JPM 2026
Biocon Biologics, the biosimilars arm of Biocon Ltd, is set to introduce three new oncology biosimilars, including a biosimilar of pembrolizumab (Keytruda), at the J.P. Morgan Healthcare Conference 2026 in San Francisco.
Biocon Biologics To Showcase Keytruda | 07/01/2026 | By Darshana | 280
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members